Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 75, Issue 5, Pages 539-555Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2019.11.046
Keywords
adipokines; adiposity; atherosclerosis; atrial fibrillation; cardiometabolic; cardiomyopathy; cardiovascular; chronic disease; dysglycemia; health; insulin; obesity; resistance; type 2 diabetes
Categories
Funding
- Amgen
- Novartis
- Novo Nordisk
- National Institutes of Health (NIH), National Heart, Lung, and Blood Institute [K23HL125991]
- University of Alabama at Birmingham - Sanofi
- Merck/Pfizer
- AstraZeneca
- Lexicon
Ask authors/readers for more resources
In the second part of this JACC State-of-the-Art Review, an early and sustainable preventive care plan is described for cardiometabolic-based chronic disease. This plan can improve cardiometabolic health by targeting early mechanistic events to decrease the risk for certain cardiovascular diseases (e.g., coronary heart disease, heart failure, and atrial fibrillation). Included are various prevention modalities, intensive lifestyle interventions, pharmacotherapy and cardiovascular outcome trial evidence, and bariatric/metabolic procedures. A tactical approach of implementing published clinical practice guidelines/algorithms for early behavioral, adiposity, and dysglycemia targeting is emphasized, as well as relevant educational and research implications. (C) 2020 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available